Autoclavable suspensions of cyclosporin A Form 2

Patent metadata

Field	Value
Publication number	US-9919028-B2
Application number	US-201615171866-A
Country	US
Kind code	B2
Filing date	Jun 2, 2016
Priority date	Nov 15, 2011
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.

First claim

What is claimed is:

1. A method of making a formulation of cyclosporin A, the method comprising the steps of
a) dissolving cyclosporin A form 2 in solution;
b) autoclaving the solution; and
c) adding a vehicle selected from the group consisting of carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, crosslinked polyacrylic acid polymers, and copolymers based on ethylene oxide and propylene oxide.

2. A method of making a formulation of cyclosporin A, the method comprising the steps of
a) dissolving in solution a vehicle selected from the group consisting of carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hyaluronic acid, polyvinylpyrrolidone, crosslinked polyacrylic acid polymers, and copolymers based on ethylene oxide and propylene oxide;
b) adding to the solution cyclosporin A Form 2; and
c) autoclaving the resulting mixture.

Assignees

• Allergan Inc

Inventors

• Blanda Wendy M
• Rivers Hongwen Ma
• Marsh David A
• Luu Michelle

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P27/04

  Artificial tears; Irrigation solutions · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/0048 Primary

  Eye, e.g. artificial tears · CPC title